[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642723":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":55,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":25,"overallStatus":77,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of Child Health Sciences and Children's Hospital, Lahore","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Meropenem Monotherapy Arm 1","EXPERIMENTAL","Patients receive meropenem IV, 30mg\u002Fkg\u002Fdose every 8 hours(maximum 2g per dose)",[13],"Drug: meropenem",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2 Title: Meropenem + Azithromycin Combination","Patients receive meropenem 30mg\u002Fkg\u002Fdose every 8 hours (maximum 2g per dose) IV plus oral azithromycin, 20 mg\u002Fkg\u002Fday.",[18],"Drug: Meropenem and azithromycin combination",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","meropenem","IV meropenem, 100 mg\u002Fkg\u002Fday TDS",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Meropenem and azithromycin combination","combination drug therapy will consist of meropenem intravenously at a dose of 20-40 mg\u002Fkg\u002Fdose every 8 hours(maximum 2g per dose) plus azithromycin (orally) at 20 mg\u002Fkg\u002Fday",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Iqra Asghar Ali, mbbs","CONTACT","+923060942498","driqraasghar@GMAIL.COM",[37],{"facility":38,"status":25,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University of Child Health Scienes Lahore","Lahore","Punjab Province","52000","Pakistan","PK",{"type":45,"coordinates":46},"Point",[47,48],74.35071,31.558,{"lat":48,"lon":47},[51,52],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"name":53,"role":54,"phone":25,"phoneExt":25,"email":25},"IQRA Asghar Ali, mbbs","PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":57,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Iqra Asghar Ali","100642723","comparison-of-single-versus-combination-drug-therapy-in-extensively-drug-resistant-salmonella-typhi-in-terms-of-time-to-defervescence-100642723",false,"NCT07641348","COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE","COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG-RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE","* Inclusion Criteria\n\n  1. Children aged 2-16 years\n  2. Culture-confirmed XDR typhoid fever (resistant to first-line agents, fluoroquinolones, and third-generation cephalosporins)\n  3. Admitted to Children's Hospital \\& Institute of Child Health, Lahore\n\nInformed consent obtained from parent\u002Fguardian\n\nExclusion Criteria\n\n1. Age \\\u003C2 years or \\>16 years\n2. Known allergy or contraindication to meropenem or azithromycin\n3. Presence of severe comorbidities (e.g., congenital heart disease, chronic renal failure, immunodeficiency)\n4. Patients already receiving carbapenem or azithromycin therapy prior to enrollment","ALL","2 Years","16 Years",{"count":69,"type":70},94,"ESTIMATED","INTERVENTIONAL",[73],"NA","This randomized controlled trial will compare the effectiveness of single-drug therapy (meropenem) versus combination therapy (meropenem plus azithromycin) in children aged 2-16 years diagnosed with extensively drug-resistant (XDR) typhoid fever at the Children's Hospital, Lahore. A total of 94 patients will be enrolled and randomly assigned to either treatment group. The primary outcome is time to defervescence, defined as sustained resolution of fever for more than 48 hours. Secondary outcomes include duration of hospital stay and complication rates. The study aims to provide evidence to guide optimal management of XDR typhoid in pediatric populations.\"",[76],"Typhoid Fever","NOT_YET_RECRUITING","2026-06-09",{"date":80,"type":81},"2026-06-11","ACTUAL",{"date":83,"type":70},"2026-07-01",{"date":85,"type":70},"2027-02-01",{"name":57,"class":6},1]